Trials / Completed
CompletedNCT00504530
r-hLIF for Improving Embryo Implantation in IVF
A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- Female
- Age
- 21 Years – 36 Years
- Healthy volunteers
- —
Summary
This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) |
Timeline
- Start date
- 2001-09-01
- Completion
- 2002-04-01
- First posted
- 2007-07-20
- Last updated
- 2017-01-04
Source: ClinicalTrials.gov record NCT00504530. Inclusion in this directory is not an endorsement.